Recently, the National Health Surveillance Agency (Anvisa) issued an informative statement regarding the use of smartwatches for glucose monitoring. This news has sparked discussions about the applicability and safety of these devices in health management, especially for people with diabetes.
In the statement, Anvisa emphasizes that there are currently no registered or authorized medical devices in Brazil for glucose monitoring through smartwatches. This raises significant questions about the reliability and accuracy of the results obtained from these devices.
It is important to note that accurate and reliable glucose monitoring is crucial for proper diabetes control and treatment decision-making. Therefore, the use of unregulated devices may pose a health risk to users.
Anvisa reinforces the need to consult qualified healthcare professionals for proper glucose monitoring and for choosing appropriate and safe devices. Additionally, it highlights the importance of following current guidelines and regulations to ensure safety and effectiveness in healthcare.
In light of this, it is essential for users to be aware of the limitations and necessary precautions when using glucose monitoring technologies, always seeking up-to-date and reliable information.
For further details and information, we recommend reading the full official statement from Anvisa, available on our blog. Check it out!
https://lnkd.in/eaRRciFy
#RegulatoryAffairs #BrisaAdvisors #BPOinRA #MedicalDevices #MedicalTechnology
Find out more about BPO in RA!
*Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br
